US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Obsidian Therapeutics, Inc.
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
October 02, 2026
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Tickers
OBX
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
August 05, 2026
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Tickers
OBX
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
August 03, 2026
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
May 21, 2026
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
April 21, 2026
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
April 14, 2026
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Tickers
GRTX
Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer
January 12, 2026
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2025
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
April 25, 2025
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Melanoma in Oral Presentation at the 2025 ASCO Annual Meeting
April 23, 2025
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and cytoDRiVE® Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
November 05, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma
September 03, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma
July 09, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Appointment of William Pao, M.D., Ph.D., to Board of Directors
June 04, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer
May 08, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting
April 24, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer
April 15, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
April 09, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development
April 03, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting
March 05, 2024
From
Obsidian Therapeutics, Inc.
Via
Business Wire
Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy
December 12, 2023
From
Obsidian Therapeutics, Inc.
Via
Business Wire
